As Covid-19 variants increasingly spread in the U.S. and abroad, new research is being published almost daily on how effectively vaccines can prevent infections by B.1.1.7, B.1.351, and other worrying variants. Here's a roundup of the latest evidence.
Early in the pandemic, major U.S. airlines stopped seating passengers in middle seats to reduce coronavirus risk exposure—but nearly all have now reversed that policy. Now, a just-released CDC study sheds light on how much the risk of coronavirus spread increases when middle seats are filled.
Scientists are exploring why some individuals who receive certain coronavirus vaccines develop a serious type of blood clot, with emerging research suggesting it may have something to do with the technology used to develop the vaccines. However, officials caution that the research is far from conclusive—and that instances of these blood clots, though meriting rigorous review, remain exceedingly rare.
Pharmaceutical executives and federal health officials say people likely will need booster shots to maintain their protection against Covid-19 and emerging coronavirus variants—but developing the boosters may strain the supply chain's capacity to produce other critical drugs and vaccines.
A new study suggests the B.1.1.7 coronavirus variant isn't more deadly than older strains, FDA authorizes the first at-home Covid-19 antibodies test, and more.
CMS in guidance issued for insurers last month in an online technical forum on GitHub said health care prices insurers are required to post under a new price transparency rule cannot be hidden from web searches, in today's bite-sized hospital and health industry news from Indiana, Maryland, and Montana.
